Markus D. Siegelin

Columbia University Irving Medical Center — United States

Medicine · Health Sciences

48h-index6.9kcitations239works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(66), Cell death mechanisms and regulation(47), Cancer, Hypoxia, and Metabolism(44), Histone Deacetylase Inhibitors Research(32), RNA Interference and Gene Delivery(24)

Publications238 total

IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis
2026Open Access
Supplementary Tables S1-S3 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
2025Open Access
Supplementary Figures S1-S6 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
2025Open Access
TMET-35. CDK12 Inhibition Synergizes with Temozolomide to Effectively Eradicate Glioblastoma
Neuro-Oncology·2025Open Access
TMET-43. IDH1(R132H) inhibitors enhance the sensitivity of IDH1-mutant glioma to cysteine deprivation and ferroptosis
Neuro-Oncology·2025· 1 citedOpen Access
RADT-33. PROGNOSTIC AND PREDICTIVE EFFECT OF AGE IN MOLECULARLY-DEFINED LOWER GRADE GLIOMAS: A REPORT FROM THE PROSPECTIVE GLIOMA RESEARCH (PROGRES) DATABASE
Neuro-Oncology·2025Open Access
Phosphoprotein profiling identifies activation of HSP27 as a potential mechanism of resistance against CUSP9v3 in medulloblastoma
Klinische Pädiatrie·2025
DDDR-56. Single-cell analysis of drug perturbations in IDH-mutant glioma
Neuro-Oncology·2025Open Access
EPID-25. Molecular Epidemiology of Adult Diffuse Gliomas in the United States
Neuro-Oncology·2025Open Access
P18.02.B COMBINED TREATMENT WITH PHOTODYNAMIC THERAPY AND BCL-XL INHIBITION HAS A PREDOMINANTLY SYNERGISTIC ANTINEOPLASTIC ACTIVITY IN MEDULLOBLASTOMA IN VITRO
Neuro-Oncology·2025Open Access
P18.01.A ACTIVATION OF HSP27 REPRESENTS A POTENTIAL MECHANISM OF RESISTANCE AGAINST THE DRUG REPURPOSING APPROACH CUSP9V3 IN MEDULLOBLASTOMA
Neuro-Oncology·2025Open Access
P18.20.B INHIBITION OF BCL-XL EMPOWERS THE ANTINEOPLASTIC ACTIVITY OF TTFIELDS IN MALIGNANT GLIOMA IN VITRO
Neuro-Oncology·2025Open Access
CDK12 regulates cellular metabolism to promote glioblastoma growth
JCI Insight·2025Open Access
Concurrent TTR and AL Amyloidosis
JACC Case Reports·2025· 1 citedOpen Access
Targeting ATF5, CEBPB, and CEBPD with Cell-Penetrating Dpep Sensitizes Tumor Cells to NK-92MI Cell Cytotoxicity
Cells·2025Open Access
Central Nervous System Metastases from Primary Lung Carcinoma: Significance of RNA Fusion Testing and Early Versus Late Metastases
Journal of Personalized Medicine·2025Open Access
Abstract 5385: Concurrent inhibition of the serine/threonine protein kinase AURKB and the fatty acid oxidation enzyme CPT1A demonstrates synthetic lethality in preclinical glioblastoma models
Cancer Research·2025
Abstract 5395: CDK12 regulates cellular metabolism to promote therapy resistance in glioblastoma
Cancer Research·2025
Targeting ATF5, CEBPB and CEBPD with Cell-Penetrating Dpep Sensitizes Tumor Cells to NK-92MI Cell Cytotoxicity
Preprints.org·2025Open Access
A cell state-specific metabolic vulnerability to GPX4-dependent ferroptosis in glioblastoma
The EMBO Journal·2024· 14 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Georg Karpel‐Massler(25), Mike‐Andrew Westhoff(21), Peter Canoll(14), Jeffrey N. Bruce(13), Trang Nguyen(10), Chang Shu(10), Marc‐Eric Halatsch(10), Yiru Zhang(8), Klaus‐Michael Debatin(7), Elena Bianchetti(7), Catarina M. Quinzii(7), Dario C. Altieri(7), Enyuan Shang(6), Nelson Humala(6), Aayushi Mahajan(6), Timo Gaiser(6), Angeliki Mela(5), Matei A. Banu(5), Alonzo H. Ross(5), Antje Habel(5)